SymBio Pharmaceuticals Management

Management criteria checks 1/4

SymBio Pharmaceuticals' CEO is Fuminori Yoshida, appointed in Mar 2005, has a tenure of 19.17 years. directly owns 2.58% of the company’s shares, worth ¥192.29M. The average tenure of the management team and the board of directors is 1.3 years and 3.2 years respectively.

Key information

Fuminori Yoshida

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	19.2yrs
CEO ownership	2.6%
Management average tenure	1.3yrs
Board average tenure	3.2yrs

Recent management updates

Recent updates

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Feb 09

If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%

Dec 18

CEO

Fuminori Yoshida (74 yo)

19.2yrs

Tenure

Mr. Fuminori Yoshida serves as President, Chief Executive Officer and Chief Operating Officer of Takeda Bio Development Center Limited. Mr. Yoshida founded SymBio Pharmaceuticals Limited in March 2005 and...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Fuminori Yoshida	CEO, President	19.2yrs	no data	2.58% ¥ 192.3m
Takaaki Fukushima	Executive Corporate Officer & CFO	no data	no data	no data
Masamichi Mizutake	Director of Finance and Accounting	no data	no data	no data
Kiwami Kurisawa	Director of General Affairs and Legal Officer	no data	no data	no data
Tatsuya Yoneyama	Senior Director of Business Development	no data	no data	no data
Shinji Kunii	Director of Sales	no data	no data	no data
Koji Fukushima	Corporate Officer & Chief Medical Officer	no data	no data	no data
Yoshiharu Torikai	Corporate Officer	no data	no data	no data
Masahiko Okuno	Corporate Officer	1.2yrs	no data	no data
Hiroyuki Horita	Corporate Officer	1.3yrs	no data	no data

1.3yrs

Average Tenure

Experienced Management: 4582's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Fuminori Yoshida	CEO, President	19.2yrs	no data	2.58% ¥ 192.3m
Robert Lewis	Member of Scientific Advisory Board	no data	no data	no data
Tsutomu Takeuchi	Member of Scientific Advisory Board	no data	no data	no data
Toshio Suda	Member of Scientific Advisory Board	no data	no data	no data
Tatsutoshi Nakahata	Member of Scientific Advisory Board	no data	no data	no data
Makoto Ogawa	Member of Scientific Advisory Board	no data	no data	no data
Toshio Heike	Member of Scientific Advisory Board	no data	no data	no data
Shigetoshi Matsumoto	Independent Outside Director	no data	no data	0.049% ¥ 3.7m
Shinji Nakao	Member of Scientific Advisory Board	no data	no data	no data
Kiyoshi Watanabe	Outside Independent Director	2.2yrs	no data	no data
Bruce David Cheson	Independent Outside Director	no data	no data	no data
Eiji Ebinuma	Independent Outside Director	3.2yrs	no data	no data

3.2yrs

Average Tenure

Experienced Board: 4582's board of directors are considered experienced (3.2 years average tenure).

SymBio Pharmaceuticals Management

Management criteria checks 1/4

Key information

Recent management updates

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 22, 2024

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 23, 2023

Less than half of directors are independent

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 24, 2021

Recent updates

First quarter 2024 earnings released: JP¥18.02 loss per share (vs JP¥0.10 profit in 1Q 2023)

Full year 2023 earnings released: JP¥49.17 loss per share (vs JP¥30.20 profit in FY 2022)

SymBio Pharmaceuticals Limited announced that it has received ¥256.5 million in funding from Evolution Capital Management LLC

Full year 2023 earnings released

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 22, 2024

SymBio Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 08, 2024

Third quarter 2023 earnings released

SymBio Pharmaceuticals Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released

SymBio Pharmaceuticals Limited to Report Q2, 2023 Results on Aug 03, 2023

New minor risk - Share price stability

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 26%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 23, 2023

SymBio Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Feb 09, 2023

Third quarter 2022 earnings released: EPS: JP¥11.32 (vs JP¥13.83 in 3Q 2021)

Symbio Pharmaceuticals Limited Revises Earnings Forecast for the Period from January 1, 2022 to December 31, 2022

SymBio Pharmaceuticals Limited to Report Q3, 2022 Results on Nov 08, 2022

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: JP¥24.36 (vs JP¥0.11 in 2Q 2021)

Symbio Pharmaceuticals Limited Revises Earning Guidance for Fiscal Year Ending December 31, 2022

SymBio Pharmaceuticals ADR - Sponsored to Be Deleted from OTC Equity

SymBio Pharmaceuticals Limited to Report Q2, 2022 Results on Aug 04, 2022

SymBio Pharmaceuticals Limited announced that it has received ¥675.76 million in funding from CVI Investments, Inc.

Investor sentiment improved over the past week

SymBio Pharmaceuticals Limited announced that it expects to receive ¥675.76 million in funding from CVI Investments, Inc.

First quarter 2022 earnings released: EPS: JP¥4.25 (vs JP¥5.47 loss in 1Q 2021)

SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year 2022

Less than half of directors are independent

SymBio Pharmaceuticals Limited to Report Q1, 2022 Results on May 11, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Third quarter 2021 earnings released: EPS JP¥13.79 (vs JP¥23.01 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥0.10 (vs JP¥27.30 loss in 2Q 2020)

First quarter 2021 earnings released

Full year 2020 earnings released: JP¥124 loss per share (vs JP¥189 loss in FY 2019)

SymBio Pharmaceuticals Limited to Report Q1, 2021 Results on May 13, 2021

New 90-day high: JP¥1,380

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Full year 2020 earnings released: JP¥124 loss per share (vs JP¥189 loss in FY 2019)

New 90-day high: JP¥895

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 24, 2021

New 90-day low: JP¥337

If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%

Third quarter 2020 earnings released: JP¥23.01 loss per share

New 90-day low: JP¥379

Symbio Pharmaceuticals Limited Receives Approval of TREAKISYM Ready-To-Dilute ('Rtd') Formulation, with Launch Expected in January 2021

New 90-day low - JP¥409

Earnings released

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure